The DOI matches its Crossref record; 109 of the 110 references it cites were found in a registry or an index.
CAR-T cell therapy: current limitations and potential strategies
Open accessAbstract
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration. In addition, the host and tumor microenvironment interactions with CAR-T cells critically alter CAR-T cell function. Furthermore, a complex workforce is required to develop and implement these treatments. In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells with improved anti-tumor activity and decreased toxicity are necessary. In this review, we discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To address this, various immunotherapeutic strategies have emerged, including adoptive cell transfer, primarily utilizing genetically modified T cells expressing chimeric antigen receptors (CAR T-cells) to recognize and eliminate cancer cells directly (Sterner and Sterner, 2021). Adjuvant therapies, such as dendritic cell, mRNA, and peptide-based vaccinations, aim to boost the patient’s anticancer”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Research works printed but not linked: 1
- Peter P. Lee (eds.) Tumor Microenvironment (Springer) https://www.springer.com/gp/book/9783030388614
Cited by
Sorted by citations
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 810
Cancer treatments: Past, present, and future
Sonkin, D., Thomas, A., & Teicher, B. A. (2024) · Cancer Genetics · doi:10.1016/j.cancergen.2024.06.002 · Cited by 597
Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications
Cerneckis, J., Cai, H., & Shi, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01809-0 · Cited by 452
Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
Gumber, D., & Wang, L. D. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103941 · Cited by 417
Modulating extracellular matrix stiffness: A strategic approach to boost cancer immunotherapy
Mai, Z., Lin, Y., Lin, P., Zhao, X., & Cui, L. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06697-4 · Cited by 398
Metabolic regulation of the immune system in health and diseases: mechanisms and interventions
Hu, T., Liu, C., Lei, M., Zeng, Q., Li, L., Tang, H., & Zhang, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01954-6 · Cited by 438
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 443
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 454
Chesney, J. A., Lewis, K. D., Kluger, H. M., Hamid, O., Whitman, E. D., Thomas, S. S., Wermke, M., Cusnir, M., Domingo‐Musibay, E., Phan, G. Q., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005755 · Cited by 381
Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Liu, Y., Fei, Z., Ali, H. A., Lathia, J. D., & Chen, P. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01226-x · Cited by 403
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z., Teng, Q., Qin, T. L., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 338
CAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens‐Arias, V., Díaz‐Beyá, M., Juan, M., Urbano-Ispizúa, Á., Esteve, J., Velasco-Hernández, T., & Menéndez, P. R. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 350
Challenges and new technologies in adoptive cell therapy
Zhang, P., Zhang, G., & Wan, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01492-8 · Cited by 291
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Farhangnia, P., Khorramdelazad, H., Nickho, H., & Delbandi, A. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01561-6 · Cited by 265
Exploiting innate immunity for cancer immunotherapy
Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 250
Chugh, V., Krishna, K. V., & Pandit, A. S. (2021) · ACS Nano · doi:10.1021/acsnano.1c03800 · Cited by 219
Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells
Agarwalla, P., Ogunnaike, E. A., Ahn, S., Froehlich, K. A., Jansson, A., Ligler, F. S., Dotti, G., & Brudno, Y. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01245-x · Cited by 216
CAR-T Cell Therapy: the Efficacy and Toxicity Balance
Chohan, K. L., Siegler, E. L., & Kenderian, S. S. (2023) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-023-00687-7 · Cited by 227
Dagar, G., Gupta, A., Masoodi, T., Nisar, S., Merhi, M., Hashem, S., Chauhan, R., Dagar, M., Mirza, S., Bagga, P., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04292-3 · Cited by 229
The CD70-CD27 axis in oncology: the new kids on the block
Flieswasser, T., den Eynde, A. V., Audenaerde, J. R. M. V., Waele, J. D., Lardon, F., Riether, C., de Haard, H., Smits, E., Pauwels, P., & Jacobs, J. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02215-y · Cited by 205
Cancer stem cells: landscape, challenges and emerging therapeutic innovations
Lee, H., Kim, B., Park, J., Park, S., Yoo, G., Yum, S., Kang, W., Lee, J., Youn, H., & Youn, B. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02360-2 · Cited by 247
Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
Saura‐Esteller, J., de Jong, M., King, L. A., Ensing, E., Winograd, B., de Gruijl, T. D., Parren, P. W. H. I., & van der Vliet, H. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915837 · Cited by 210
Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy
Liu, Z., Zhou, Z., Dang, Q., Xu, H. M., Lv, J., Li, H., & Han, X. (2022) · Theranostics · doi:10.7150/thno.76854 · Cited by 200
Choi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
Magré, L., Verstegen, M. M. A., Buschow, S. I., van der Laan, L. J. W., Peppelenbosch, M. P., & Desai, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006290 · Cited by 201
Agarwal, S., Aznar, M. A., Rech, A. J., Good, C. R., Kuramitsu, S., Da, T., Gohil, M., Chen, L., Hong, S.-J. A., Ravikumar, P., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.001 · Cited by 199
Extracellular targeted protein degradation: an emerging modality for drug discovery
Wells, J. A., & Kumru, K. S. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00833-z · Cited by 202
Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells
Jin, K., Qian, C., Lin, J., & Liu, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1099811 · Cited by 199
Critical role of the gut microbiota in immune responses and cancer immunotherapy
Li, Z., Xiong, W., Zhu, L. W., Wang, J., Zeng, Z., Kołat, D., Li, X., Zhou, D., Xu, X., & Zhao, L.-Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01541-w · Cited by 197
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment
Bui, T. A., Mei, H., Sang, R., Gallego‐Ortega, D., & Deng, W. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105266 · Cited by 190
Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity
Savage, T. M., Vincent, R. L., Rae, S. S., Huang, L., Ahn, A., Pu, K., Li, F., Santos, K. D. L., Coker, C., Danino, T., et al. (2023) · Science Advances · doi:10.1126/sciadv.adc9436 · Cited by 168
Targeting of TAMs: can we be more clever than cancer cells?
Kzhyshkowska, J. G., Shen, J., & Larionova, I. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01232-z · Cited by 187
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 169
Next generations of CAR-T cells - new therapeutic opportunities in hematology?
Tomasik, J., Jasiński, M., & Basak, G. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1034707 · Cited by 166
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Chen, T. R., Wang, M., Chen, Y., & Liu, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03315-3 · Cited by 170
Alnefaie, A., Albogami, S. M., Asiri, Y. A., Ahmad, T., Alotaibi, S. S., Al-Sanea, M. M., & Althobaiti, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.797440 · Cited by 163
iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting
Goldenson, B. H., Hor, P., & Kaufman, D. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.841107 · Cited by 154
In vivo chimeric antigen receptor (CAR)-T cell therapy
Bot, A., Scharenberg, A. M., Friedman, K. M., Guey, L. T., Hofmeister, R., Andorko, J. I., Klichinsky, M., Neumann, F., Shah, J. V., Swayer, A. J., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01291-5 · Cited by 172
In vivo CAR engineering for immunotherapy
Li, Y.-R., Zhu, Y., Halladay, T., & Yang, L. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01174-1 · Cited by 151
Co-Stimulatory Receptor Signaling in CAR-T Cells
Honikel, M. M., & Olejniczak, S. H. (2022) · Biomolecules · doi:10.3390/biom12091303 · Cited by 149
Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo
Zhou, J., Sun, L., Jia, Y., Wang, Z., Luo, T., Tan, J., Fang, X., Zhu, H., Wang, J., Yu, L., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.033 · Cited by 141
Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer
Jin, X., Liu, Z., Yang, D., Yin, K., & Chang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.948647 · Cited by 142
Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma
Liu, Z., Zhou, J., Yang, X., Liu, Y., Zou, C., Lv, W., Chen, C., Cheng, K. K. Y., Chen, T., Chang, L., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01711-9 · Cited by 134
Bhatia, V., Kamat, N. V., Pariva, T. E., Wu, L., Tsao, A., Sasaki, K., Sun, H., Javier, G., Nutt, W. S., Coleman, I. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37874-2 · Cited by 138
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals
Menon, D., & Bril, V. (2022) · Drugs · doi:10.1007/s40265-022-01726-y · Cited by 135
Eosinophil–lymphocyte interactions in the tumor microenvironment and cancer immunotherapy
Grisaru‐Tal, S., Rothenberg, M. E., & Munitz, A. (2022) · Nature Immunology · doi:10.1038/s41590-022-01291-2 · Cited by 131
Myasthenia gravis: the changing treatment landscape in the era of molecular therapies
Iorio, R. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-023-00916-w · Cited by 140
Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies
Lin, H., Yang, X., Ye, S., Huang, L., & Mu, W. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117252 · Cited by 134
Gong, Z., Li, Q., Shi, J., Li, P., Hua, L., Shultz, L. D., & Ren, G. (2023) · Science Immunology · doi:10.1126/sciimmunol.add5204 · Cited by 130
Recent Advances in Molecular Mechanisms of Cancer Immunotherapy
Kciuk, M., Yahya, E. B., Mohamed, M. M. I., Rashid, S., Iqbal, M. O., Kontek, R., Abdulsamad, M. A., & Allaq, A. A. (2023) · Cancers · doi:10.3390/cancers15102721 · Cited by 135
Drug discovery is an eternal challenge for the biomedical sciences
Li, H., Wei, W., & Xu, H. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-1001 · Cited by 120
Advances in NK cell production
Fang, F., Xie, S., Chen, M., Li, Y., Yue, J., Ma, J., Shu, X., He, Y., Xiao, W., & Tian, Z. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00808-3 · Cited by 132
Revolutionizing Neurocare: Biomimetic Nanodelivery Via Cell Membranes
Liao, J., Gong, L., Xu, Q., Wang, J., Yang, Y., Zhang, S., Dong, J., Lin, K., Liang, Z., Sun, Y., et al. (2024) · Advanced Materials · doi:10.1002/adma.202402445 · Cited by 126
Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms
Michels, A., Ho, N., & Buchholz, C. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.018 · Cited by 131
Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies
Muhammad, S., Fan, T. T., Hai, Y., Gao, Y., & He, J. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01826-7 · Cited by 130
Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations
Lee, K.-W., Yam, J. W. P., & Mao, X. (2023) · Cells · doi:10.3390/cells12172147 · Cited by 130
Logun, M. T., Wang, X., Sun, Y. Y., Bagley, S. J., Li, N., Desai, A. S., Zhang, D. Y., Nasrallah, M. P., Pai, E. L.-L., Oner, B. S., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.11.010 · Cited by 127
Improving CAR T-Cell Persistence
Pietrobon, V., Todd, L. A., Goswami, A., Stefanson, O., Yang, Z., & Marincola, F. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910828 · Cited by 124
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
Gajra, A., Zalenski, A. A., Sannareddy, A., Jeune‐Smith, Y., Kapinos, K. A., & Kansagra, A. J. (2022) · Pharmaceutical Medicine · doi:10.1007/s40290-022-00428-w · Cited by 124
Doglio, M., Ugolini, A., Bercher-Brayer, C., Camisa, B., Toma, C., Norata, R., Rosso, S. D., Greco, R., Ciceri, F., Sanvito, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46448-9 · Cited by 128
Regulatory T cells in the tumour microenvironment
Imianowski, C. J., Chen, Q., Workman, C. J., & Vignali, D. A. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00832-9 · Cited by 144
Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
Sterner, R. C., & Sterner, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.879608 · Cited by 121
Self-citationTargeting the Siglec–Sialic Acid Immune Axis in Cancer: Current and Future Approaches
Laubli, H. P., Nalle, S. C., & Maslyar, D. J. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0366 · Cited by 117
Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting
Lee, E. H. J., Murad, J. P., Christian, L., Gibson, J., Yamaguchi, Y., Cullen, C., Gumber, D., Park, A. K., Young, C. A., Monroy, I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40115-1 · Cited by 121
Hughes, A. M., & Hu, N. (2023) · Cancers · doi:10.3390/cancers15164091 · Cited by 121
Jacobson, C. A., Munoz, J. L., Sun, F., Kanters, S., Limbrick‐Oldfield, E. H., Spooner, C., Mignone, K., Ayuk, F. A., Sanderson, R., Whitmore, J. B., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.10.017 · Cited by 114
Jia, K., Chen, Y., Sun, Y. L., Hu, Y., Jiao, L., Ma, J., Yuan, J., Qi, C., Li, Y., Gong, J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02421-1 · Cited by 118
Cesur, B., & Dora, D. D. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3550 · Cited by 112
Therapeutic potential of CAR T cell in malignancies: A scoping review
Mehrabadi, A. Z., Ranjbar, R., Farzanehpour, M., Shahriary, A., Dorostkar, R., Hamidinejad, M. A., & Ghaleh, H. E. G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112512 · Cited by 116
Mechanistic study of cancer drug delivery: Current techniques, limitations, and future prospects
Imtiaz, S., Ferdous, U. T., Nizela, A., Hasan, A., Shakoor, A., Zia, A. W., & Uddin, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117535 · Cited by 119
Xin, T., Li, C., Zhou, C., Zhao, Y., Hu, Z., & Wu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809754 · Cited by 115
CAR T Cell Therapy: A Versatile Living Drug
Marco, R. C. D., Monzó, H. J., & Ojala, P. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076300 · Cited by 120
Engineering synthetic RNA devices for cell control
Dykstra, P. B., Kaplan, M., & Smolke, C. D. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00436-7 · Cited by 119
Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment
Mun, J.-Y., Leem, S., Lee, J. H., & Kim, H. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864739 · Cited by 113
Microbial short-chain fatty acids: a strategy to tune adoptive T cell therapy
Rangan, P., & Mondino, A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004147 · Cited by 111
Shahvali, S., Rahiman, N., Jaafari, M. R., & Arabi, L. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01308-9 · Cited by 106
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
Luo, X., He, X., Zhang, X., Zhao, X., Zhang, Y., Shi, Y., & Hua, S. (2024) · MedComm · doi:10.1002/mco2.474 · Cited by 115
Zhang, L., Zhang, W., Li, Z., Lin, S., Zheng, T., Hao, B., Hou, Y., Zhang, Y., Wang, K., Qin, C., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02439-6 · Cited by 113
CAR-T cell potency: from structural elements to vector backbone components
Mazinani, M., & Rahbarizadeh, F. (2022) · Biomarker Research · doi:10.1186/s40364-022-00417-w · Cited by 111
Advances in immunotherapy for glioblastoma multiforme
Mahmoud, A. B., Ajina, R., Aref, S., Darwish, M., Alsayb, M. A., Taher, M., Alsharif, S. T., Hashem, A. M., & Alkayyal, A. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944452 · Cited by 103
Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics
Bhat, A. A., Nisar, S., Mukherjee, S., Saha, N., Yarravarapu, N., Lone, S. N., Masoodi, T., Chauhan, R., Maacha, S., Bagga, P., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03765-1 · Cited by 114
Budde, L. E., Olszewski, A. J., Assouline, S. E., Lossos, I. S., Diefenbach, C., Kamdar, M. K., Ghosh, N., Modi, D., Sabry, W., Naik, S. G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02726-5 · Cited by 105
Lipid nanoparticles: Composition, formulation, and application
Xu, S., Hu, Z., Song, F., Xu, Y. G., & Han, X. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101463 · Cited by 115
Tumor organoid-immune co-culture models: exploring a new perspective of tumor immunity
Wang, J., Tao, X., Zhu, J., Dai, Z., Du, Y., Xie, Y., Chu, X., Fu, G., & Lei, Z. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02407-x · Cited by 101
The next frontier in immunotherapy: potential and challenges of CAR-macrophages
Li, J., Chen, P., & Ma, W. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00549-9 · Cited by 112
Therapeutic targeting of DNA methylation alterations in cancer
Lee, A. V., Nestler, K. A., & Chiappinelli, K. B. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108640 · Cited by 105
Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review
Zakari, S., Kaze, N. N., Olagunju, G. V., Nnaji, P. C., Ogunniyi, O. B., Tebamifor, M. E., Israel, E. N., Atawodi, S. E.-O., & Ogunlana, O. O. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1405267 · Cited by 104
Ando, S., Perkins, C. M., Sajiki, Y., Chastain, C., Valanparambil, R. M., Wieland, A., Hudson, W. H., Hashimoto, M., Ramalingam, S. S., Freeman, G. J., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160025 · Cited by 96
The application of HER2 and CD47 CAR-macrophage in ovarian cancer
Chen, Y., Zhu, X., Liu, H., Wang, C., Chen, Y., Wang, H., Fang, Y., Wu, X., Xu, Y., Li, C., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04479-8 · Cited by 105
Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
Babamohamadi, M., Mohammadi, N., Faryadi, E., Haddadi, M., Merati, A., Ghobadinezhad, F., Amirian, R., Izadi, Z., & Hadjati, J. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06391-x · Cited by 104
Derraz, B., Breda, G., Kaempf, C., Baenke, F., Cotte, F., Reiche, K., Köhl, U., Kather, J. N., Eskenazy, D., & Gilbert, S. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00517-w · Cited by 94
CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)
Sun, D., Shi, X., Li, S., Wang, X., Xiao, Y., & Wan, M. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13171 · Cited by 110
Hamdy, N. Μ., Basalious, E. B., El-Sisi, M. G., Nasr, M., Kabel, A. M., Nossier, E. S., & Abadi, A. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2416985 · Cited by 95
Frontiers in CAR-T cell therapy for autoimmune diseases
Li, Y.-R., Lyu, Z., Chen, Y., Fang, Y., & Yang, L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.07.005 · Cited by 97
Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives
Huang, C. L., Li, J., Wu, R., Li, Y., & Zhang, C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02344-4 · Cited by 116
Interleukin 15 in Cell-Based Cancer Immunotherapy
Zhou, Y., Husman, T., Cen, X., Tsao, T., Brown, J., Bajpai, A., Li, M., Zhou, K., & Yang, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137311 · Cited by 92
Metadata
- Authors
- Sterner, R. C., & Sterner, R. M.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Sterner, Rosalie M.
- Venue
- Blood Cancer Journal
- Published
- 2021-04-06
- Volume
- 11
- Issue
- 4
- Pages
- 69-69
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC8024391
- OpenAlex
- W3148729173
- Cited by
- 2,926
- References
- 110
- Citations by year
- 2026: 530 · 2025: 806 · 2024: 726 · 2023: 532 · 2022: 287 · 2021: 42
- FWCI
- 48.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Wisconsin-Madison (T32-GM008692)
- Regenerative Medicine Minnesota (RMM 012819 EPC 003)
- National Institute of General Medical Sciences (T32GM008692)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- CAR T-cell therapy, chimeric antigen receptor, solid tumors, hematologic malignancies, CAR-T cell engineering, tumor microenvironment, antigen escape, CAR-T toxicity, tumor infiltration
- MeSH terms
- Receptors, Chimeric Antigen, Animals, Humans, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Hematologic Neoplasms, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
